The  ||| S:0 E:4 ||| DT
use  ||| S:4 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
immunoglobulin  ||| S:11 E:26 ||| JJ
therapy  ||| S:26 E:34 ||| NN
for  ||| S:34 E:38 ||| IN
patients  ||| S:38 E:47 ||| NNS
undergoing  ||| S:47 E:58 ||| VBG
solid  ||| S:58 E:64 ||| JJ
organ  ||| S:64 E:70 ||| NN
transplantation ||| S:70 E:85 ||| NN
:  ||| S:85 E:87 ||| :
an  ||| S:87 E:90 ||| DT
evidence-based  ||| S:90 E:105 ||| JJ
practice  ||| S:105 E:114 ||| NN
guideline  ||| S:114 E:124 ||| VBD
This  ||| S:124 E:129 ||| DT
guideline  ||| S:129 E:139 ||| NN
for  ||| S:139 E:143 ||| IN
the  ||| S:143 E:147 ||| DT
use  ||| S:147 E:151 ||| NN
of  ||| S:151 E:154 ||| IN
immunoglobulin  ||| S:154 E:169 ||| NNS
( ||| S:169 E:170 ||| -LRB-
IG ||| S:170 E:172 ||| NNP
)  ||| S:172 E:174 ||| -RRB-
for  ||| S:174 E:178 ||| IN
sensitized  ||| S:178 E:189 ||| JJ
patients  ||| S:189 E:198 ||| NNS
undergoing  ||| S:198 E:209 ||| VBG
solid  ||| S:209 E:215 ||| JJ
organ  ||| S:215 E:221 ||| NN
transplantation  ||| S:221 E:237 ||| NN
( ||| S:237 E:238 ||| -LRB-
SOT ||| S:238 E:241 ||| NNP
)  ||| S:241 E:243 ||| -RRB-
is  ||| S:243 E:246 ||| VBZ
an  ||| S:246 E:249 ||| DT
initiative  ||| S:249 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
the  ||| S:263 E:267 ||| DT
Canadian  ||| S:267 E:276 ||| JJ
Blood  ||| S:276 E:282 ||| NNP
Services  ||| S:282 E:291 ||| NNPS
and  ||| S:291 E:295 ||| CC
the  ||| S:295 E:299 ||| DT
National  ||| S:299 E:308 ||| NNP
Advisory  ||| S:308 E:317 ||| NNP
Committee  ||| S:317 E:327 ||| NNP
on  ||| S:327 E:330 ||| IN
Blood  ||| S:330 E:336 ||| NNP
and  ||| S:336 E:340 ||| CC
Blood  ||| S:340 E:346 ||| NNP
Products  ||| S:346 E:355 ||| NNPS
of  ||| S:355 E:358 ||| IN
Canada  ||| S:358 E:365 ||| NNP
to  ||| S:365 E:368 ||| TO
( ||| S:368 E:369 ||| -LRB-
1 ||| S:369 E:370 ||| LS
)  ||| S:370 E:372 ||| -RRB-
provide  ||| S:372 E:380 ||| VBP
guidance  ||| S:380 E:389 ||| VBN
for  ||| S:389 E:393 ||| IN
Canadian  ||| S:393 E:402 ||| JJ
practitioners  ||| S:402 E:416 ||| NNS
involved  ||| S:416 E:425 ||| VBN
in  ||| S:425 E:428 ||| IN
the  ||| S:428 E:432 ||| DT
care  ||| S:432 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
patients  ||| S:440 E:449 ||| NNS
undergoing  ||| S:449 E:460 ||| VBG
SOT  ||| S:460 E:464 ||| NNP
and  ||| S:464 E:468 ||| CC
transfusion  ||| S:468 E:480 ||| JJ
medicine  ||| S:480 E:489 ||| NN
specialists  ||| S:489 E:501 ||| NNS
on  ||| S:501 E:504 ||| IN
the  ||| S:504 E:508 ||| DT
use  ||| S:508 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
IG  ||| S:515 E:518 ||| NNP
and  ||| S:518 E:522 ||| CC
( ||| S:522 E:523 ||| -LRB-
2 ||| S:523 E:524 ||| LS
)  ||| S:524 E:526 ||| -RRB-
standardize  ||| S:526 E:538 ||| JJ
care ||| S:538 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
limit  ||| S:544 E:550 ||| VB
adverse  ||| S:550 E:558 ||| JJ
events ||| S:558 E:564 ||| NNS
,  ||| S:564 E:566 ||| ,
and  ||| S:566 E:570 ||| CC
optimize  ||| S:570 E:579 ||| JJ
patient  ||| S:579 E:587 ||| NN
care ||| S:587 E:591 ||| NN
.  ||| S:591 E:593 ||| .
A  ||| S:593 E:595 ||| DT
systematic  ||| S:595 E:606 ||| JJ
expert  ||| S:606 E:613 ||| NN
and  ||| S:613 E:617 ||| CC
bibliography  ||| S:617 E:630 ||| JJ
literature  ||| S:630 E:641 ||| NN
search  ||| S:641 E:648 ||| NN
up  ||| S:648 E:651 ||| RP
to  ||| S:651 E:654 ||| TO
July  ||| S:654 E:659 ||| NNP
2008  ||| S:659 E:664 ||| CD
was  ||| S:664 E:668 ||| VBD
conducted ||| S:668 E:677 ||| VBN
,  ||| S:677 E:679 ||| ,
with  ||| S:679 E:684 ||| IN
791  ||| S:684 E:688 ||| CD
literature  ||| S:688 E:699 ||| NN
citations  ||| S:699 E:709 ||| NNS
and  ||| S:709 E:713 ||| CC
45  ||| S:713 E:716 ||| CD
reports  ||| S:716 E:724 ||| NNS
reviewed ||| S:724 E:732 ||| VBN
.  ||| S:732 E:734 ||| .
To  ||| S:734 E:737 ||| TO
validate  ||| S:737 E:746 ||| VB
the  ||| S:746 E:750 ||| DT
recommendations ||| S:750 E:765 ||| NNS
,  ||| S:765 E:767 ||| ,
the  ||| S:767 E:771 ||| DT
guideline  ||| S:771 E:781 ||| NN
was  ||| S:781 E:785 ||| VBD
sent  ||| S:785 E:790 ||| VBN
to  ||| S:790 E:793 ||| TO
physicians  ||| S:793 E:804 ||| VB
involved  ||| S:804 E:813 ||| VBN
in  ||| S:813 E:816 ||| IN
SOT  ||| S:816 E:820 ||| NNP
in  ||| S:820 E:823 ||| IN
Canada  ||| S:823 E:830 ||| NNP
and  ||| S:830 E:834 ||| CC
a  ||| S:834 E:836 ||| DT
patient  ||| S:836 E:844 ||| JJ
representative ||| S:844 E:858 ||| NN
.  ||| S:858 E:860 ||| .
The  ||| S:860 E:864 ||| DT
recommendations  ||| S:864 E:880 ||| NNS
identify  ||| S:880 E:889 ||| VBP
( ||| S:889 E:890 ||| -LRB-
1 ||| S:890 E:891 ||| LS
)  ||| S:891 E:893 ||| -RRB-
sensitized  ||| S:893 E:904 ||| JJ
patients  ||| S:904 E:913 ||| NNS
undergoing  ||| S:913 E:924 ||| VBG
SOT  ||| S:924 E:928 ||| NNS
that  ||| S:928 E:933 ||| WDT
would  ||| S:933 E:939 ||| MD
have  ||| S:939 E:944 ||| VB
a  ||| S:944 E:946 ||| DT
better  ||| S:946 E:953 ||| JJR
survival  ||| S:953 E:962 ||| NN
and  ||| S:962 E:966 ||| CC
decreased  ||| S:966 E:976 ||| JJ
morbidity  ||| S:976 E:986 ||| NN
by  ||| S:986 E:989 ||| IN
receiving  ||| S:989 E:999 ||| VBG
IG  ||| S:999 E:1002 ||| NNP
preoperatively ||| S:1002 E:1016 ||| NN
,  ||| S:1016 E:1018 ||| ,
postoperatively ||| S:1018 E:1033 ||| NN
,  ||| S:1033 E:1035 ||| ,
and  ||| S:1035 E:1039 ||| CC
for  ||| S:1039 E:1043 ||| IN
the  ||| S:1043 E:1047 ||| DT
treatment  ||| S:1047 E:1057 ||| NN
of  ||| S:1057 E:1060 ||| IN
organ  ||| S:1060 E:1066 ||| JJ
rejection ||| S:1066 E:1075 ||| NN
;  ||| S:1075 E:1077 ||| :
( ||| S:1077 E:1078 ||| -LRB-
2 ||| S:1078 E:1079 ||| LS
)  ||| S:1079 E:1081 ||| -RRB-
patients  ||| S:1081 E:1090 ||| NNS
who  ||| S:1090 E:1094 ||| WP
may  ||| S:1094 E:1098 ||| MD
not  ||| S:1098 E:1102 ||| RB
have  ||| S:1102 E:1107 ||| VB
any  ||| S:1107 E:1111 ||| DT
benefit  ||| S:1111 E:1119 ||| NN
from  ||| S:1119 E:1124 ||| IN
receiving  ||| S:1124 E:1134 ||| VBG
IG ||| S:1134 E:1136 ||| NNP
;  ||| S:1136 E:1138 ||| :
and  ||| S:1138 E:1142 ||| CC
( ||| S:1142 E:1143 ||| -LRB-
3 ||| S:1143 E:1144 ||| LS
)  ||| S:1144 E:1146 ||| -RRB-
potential  ||| S:1146 E:1156 ||| JJ
adversities  ||| S:1156 E:1168 ||| NN
to  ||| S:1168 E:1171 ||| TO
IG ||| S:1171 E:1173 ||| NNP
.  ||| S:1173 E:1175 ||| .
